Octreotide vs Lanreotide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicOctreotideLanreotide
What it is

A somatostatin analogue. The label states that it acts like natural somatostatin and is an even more potent inhibitor of growth hormone, glucagon and insulin.1

A somatostatin analogue. The label describes lanreotide as an octapeptide, eight amino acids long, that is thought to act like natural somatostatin.6

FDA status

FDA-approved

FDA-approved as Sandostatin and other octreotide products1,2,3,4,5

FDA-approved. Drugs@FDA lists Sandostatin with an original approval date of October 21, 1988, and later octreotide products including Sandostatin LAR, Mycapssa and Bynfezia. The cited label has no boxed warning.1,2,3,4,5

Is octreotide FDA-approved?

FDA-approved

FDA-approved as Somatuline Depot and other lanreotide products6,7,8,9

FDA-approved. Drugs@FDA lists Somatuline Depot with an original approval date of August 30, 2007, and later lanreotide applications. The cited label has no boxed warning.6,7,8,9

Is lanreotide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.10

Not among the six peptides the policy lists.10

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Smaller controlled human trials

  • Controlled human trial Sandostatin LAR: a six-month trial in 93 people with malignant carcinoid syndrome who had responded to Sandostatin, 67 randomized to three blinded strengths of Sandostatin LAR and 26 continuing unblinded on Sandostatin, described in the Sandostatin LAR label.11
  • Controlled human trial Mycapssa: a nine-month randomized, double-blind, placebo-controlled trial in 56 people with acromegaly, described in the Mycapssa label as the trial that established its efficacy.12
  • Controlled human trial A double-blind, randomized, placebo-controlled trial of octreotide in 20 people with acromegaly, published in 1990, that measured growth hormone and IGF-1 over 14 days.13
  • Controlled human trial MPOWERED: an open-label, randomized Phase 3 trial in 92 adults with acromegaly who had already responded to treatment, comparing Mycapssa with the somatostatin-analogue treatment they had been receiving.14
  • Small, short, or incompletely reported human study Sandostatin LAR: three trials in people with acromegaly already controlled on Sandostatin who switched to Sandostatin LAR (101 people in two trials and 151 in a third), and two open-label studies in 143 untreated people, described in the Sandostatin LAR label.11

Smaller controlled human trials

  • Controlled human trial A randomized, double-blind, placebo-controlled trial in 204 people with advanced, well or moderately differentiated gastroenteropancreatic neuroendocrine tumors, with progression-free survival as the main outcome.6
  • Controlled human trial A 16-week randomized, double-blind, placebo-controlled trial in 115 people with neuroendocrine tumors and carcinoid syndrome.6
  • Controlled human trial A one-year acromegaly study in 108 people that began with a 4-week double-blind, placebo-controlled phase.6
Records collected

57 ClinicalTrials.gov records and 64 PubMed records collected

13 ClinicalTrials.gov records and 49 PubMed records collected

Area of study

Hormones, Cancer1

Hormones, Cancer6

Latest dated events
  1. DailyMed publishes the octreotide label version cited on this page.1
  2. FDA approves Bynfezia, according to Drugs@FDA.5
  3. The Sandostatin LAR and Mycapssa labels cited on this page are revised in July 2024.11,12
  1. DailyMed publishes the lanreotide label version cited on this page.6
  2. FDA approves a generic lanreotide application, according to Drugs@FDA.9
  3. FDA approves a further lanreotide application, according to Drugs@FDA.8

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Octreotide acetate injection, solution · SPL version 2 · published 2026-02-02 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    Drugs@FDA application NDA019667 · original submission status AP · 1988-10-21 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  3. 3
    Drugs@FDA application NDA021008 · original submission status AP · 1998-11-25 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  4. 4
    Drugs@FDA application NDA208232 · original submission status AP · 2020-06-26 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Drugs@FDA application NDA213224 · original submission status AP · 2024-09-27 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Lanreotide acetate injection · SPL version 3 · published 2025-06-02 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  7. 7
    Drugs@FDA application NDA022074 · original submission status AP · 2007-08-30 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  8. 8
    Drugs@FDA application NDA215395 · original submission status AP · 2021-12-17 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  9. 9
    Drugs@FDA application ANDA217193 · original submission status AP · 2024-05-21 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  10. 10
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  11. 11
    Sandostatin LAR Depot (octreotide acetate) prescribing information, NDA 021008 supplement S-049, revised July 2024 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  12. 12
    Mycapssa (octreotide) prescribing information, NDA 208232 supplement S-006, revised July 2024 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  13. 13
    Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects (1990) · PMID 2229278 ↗

    The Journal of Clinical Endocrinology & Metabolism · Official source · Source checked November 14, 2026

  14. 14
    Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial (MPOWERED, 2022) · PMID 34953531 ↗

    The Lancet Diabetes & Endocrinology · Official source · Source checked November 14, 2026